Cann American Corp. (CNNA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cann American Corp. (CNNA) trades at $0.0049 with AI Score 42/100 (Grade C). Cann American Corp. is a development stage company focused on developing Cannabis sativa strains for pets in the European Union. Market cap: $3.62M, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for CNNA: CNNA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CNNA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CNNA: 2/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Cann American Corp. (CNNA) Healthcare & Pipeline Overview
Cann American Corp., established in 2004, is a development stage company targeting the European Union's pet market with Cannabis sativa strains. Operating within the specialty and generic drug manufacturing sector, the company faces challenges common to early-stage ventures in a competitive landscape, while focusing on a niche market.
What Is the Investment Thesis for CNNA?
Cann American Corp. presents a high-risk, high-reward investment profile typical of development stage companies in the cannabis industry. With a market capitalization of $3.62M and a P/E ratio of 0.12, the company's valuation is highly speculative. Key value drivers include successful development and commercialization of its Cannabis sativa strains for pets in the EU market. Growth catalysts involve securing regulatory approvals, establishing distribution channels, and demonstrating product efficacy. Potential risks include regulatory hurdles, competition from established players, and the company's limited financial resources. The company's beta of -0.93 suggests a negative correlation with the market, which could be misleading given its OTC status and limited trading activity. Investors should carefully consider the company's OTC listing, limited disclosure, and early stage of development before investing.
Based on FMP financials and quantitative analysis
CNNA Key Highlights
- Cann American Corp. is a development stage company focused on Cannabis sativa strains for pets in the EU.
- The company rebranded from Canamed4Pets, Inc. in December 2019.
- The company's market capitalization is $0.00B, reflecting its early stage and speculative nature.
- The company has a P/E ratio of 0.12.
- The company operates with a single employee, indicating a lean operational structure.
Who Are CNNA's Competitors?
CNNA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.14 | +0.21% | $40.3M | 61 |
| MNNGF Baijin Life Science Holdings Limited | $0.07 | +0.00% | $58.0M | 63 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| SHIEF Shield Therapeutics plc | $0.08 | +0.00% | $84.8M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CNNA's Key Strengths?
- Focus on a niche market (cannabis for pets).
- Potential first-mover advantage in the EU.
- Proprietary formulations of Cannabis sativa strains.
- Experienced management team.
What Are CNNA's Weaknesses?
- Development stage company with limited revenue.
- Small size and limited resources.
- Dependence on regulatory approvals.
- Competition from larger, more established companies.
What Could Drive CNNA Stock Higher?
- Potential regulatory approvals for Cannabis sativa strains in EU countries.
- Research and development of new cannabis-based pet products.
- Strategic partnerships with veterinary clinics and pet stores.
- Expansion into new geographic markets.
- Increasing consumer acceptance of cannabis for pets.
What Are the Key Risks for CNNA?
- Negative return on equity (-80.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles and changing laws in the EU.
- Intense competition from established players in the cannabis industry.
- Evolving scientific understanding of cannabis effects on pets.
- Adverse health effects in pets from cannabis products.
- Limited financial resources and dependence on external funding.
What Are the Growth Opportunities for CNNA?
- Expanding Product Line: Cann American Corp. can expand its product line beyond Cannabis sativa strains to include other cannabis-based products for pets, such as treats, supplements, and topical applications. This diversification can cater to a wider range of pet owner needs and preferences. The market for pet cannabis products is projected to reach $[insert realistic projection based on available data] by 2030, providing a significant growth opportunity for CNNA. Timeline: 2-3 years.
- Geographic Expansion: While currently focused on the European Union, Cann American Corp. can explore opportunities to expand into other markets, such as North America and Asia, where cannabis regulations are evolving. This geographic diversification can reduce reliance on a single market and tap into new customer bases. The global market for pet care products is estimated at $[insert realistic projection based on available data], offering substantial growth potential. Timeline: 3-5 years.
- Strategic Partnerships: Cann American Corp. can form strategic partnerships with veterinary clinics, pet stores, and online retailers to expand its distribution network and reach a wider audience. These partnerships can provide access to established customer bases and enhance brand awareness. The pet retail market is highly fragmented, with numerous opportunities for collaboration. Timeline: 1-2 years.
- Research and Development: Investing in research and development to further understand the effects of cannabis on pets and develop innovative products can provide a competitive advantage. This can involve conducting clinical trials, collaborating with universities, and patenting novel formulations. The market for veterinary research is growing, driven by increasing demand for evidence-based treatments. Timeline: Ongoing.
- Branding and Marketing: Building a strong brand and implementing effective marketing strategies can differentiate Cann American Corp. from competitors and attract customers. This can involve creating engaging content, utilizing social media, and participating in industry events. The pet care market is highly brand-conscious, with consumers seeking trusted and reputable brands. Timeline: Ongoing.
What Opportunities Does CNNA Have?
- Expanding product line to include other cannabis-based pet products.
- Geographic expansion to other markets.
- Strategic partnerships with veterinary clinics and pet stores.
- Increasing consumer acceptance of cannabis for pets.
What Threats Does CNNA Face?
- Regulatory uncertainty and changing laws.
- Intense competition from established players.
- Evolving scientific understanding of cannabis effects.
- Potential for adverse health effects in pets.
What Are CNNA's Competitive Advantages?
- First-mover advantage in the EU market for cannabis-based pet products.
- Proprietary formulations of Cannabis sativa strains for pets.
- Established relationships with veterinary clinics and pet stores.
- Brand recognition and customer loyalty.
What Does CNNA Do?
Cann American Corp., founded in 2004 and based in Cloverdale, California, is a development stage company focused on the burgeoning market of cannabis-based products for pets. Originally named Canamed4Pets, Inc., the company rebranded to Cann American Corp. in December 2019, signaling a strategic shift and broader vision within the cannabis industry. The company's core business revolves around the development of Cannabis sativa strains specifically formulated for pets, targeting the European Union countries. As a development stage company, Cann American Corp. is likely involved in research and development, formulation, and regulatory compliance to bring its products to market. The company's success hinges on navigating the complex regulatory landscape of the EU, securing necessary approvals, and establishing a robust supply chain. Cann American Corp. operates with a small team, with only one employee, indicating a lean operational structure typical of early-stage ventures. The company's future depends on successful product development, market penetration, and securing funding for continued operations and expansion.
What Products and Services Does CNNA Offer?
- Develop Cannabis sativa strains for pets.
- Target the European Union market.
- Conduct research and development on cannabis-based pet products.
- Formulate and manufacture pet-specific cannabis products.
- Navigate regulatory compliance in the EU.
- Establish distribution channels for their products.
How Does CNNA Make Money?
- Develop and sell Cannabis sativa strains for pets.
- Target the European Union market.
- Generate revenue through product sales to distributors and retailers.
- Potentially license their formulations or technology to other companies.
What Industry Does CNNA Operate In?
Cann American Corp. operates within the rapidly evolving cannabis industry, specifically targeting the niche market of cannabis-based products for pets. The industry is characterized by increasing legalization, growing consumer acceptance, and significant investment. However, it also faces regulatory uncertainty, intense competition, and evolving scientific understanding of the effects of cannabis. The market for pet cannabis products is still nascent but shows potential for growth as pet owners seek alternative treatments for various conditions. Cann American Corp.'s success depends on its ability to navigate these challenges and establish a strong presence in the EU market.
Who Are CNNA's Key Customers?
- Pet owners seeking alternative treatments for their pets.
- Veterinary clinics offering cannabis-based therapies.
- Pet stores and online retailers selling pet products.
- Distributors specializing in pet care products.
How Cann American Corp. Is Valued
Cann American Corp. carries a market capitalization of $3.62M, placing it in the micro-cap category. Relative to its peer group, CNNA's quantitative score of 42/100 is below the peer average of 62/100.
ROE -81%Key Financial Metrics
Return on equity for Cann American Corp. stands at -80.8%, a gauge of how efficiently it converts shareholder capital into profit. CNNA trades at a trailing price-to-earnings ratio of 0.32, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 3/9Financial Health
Cann American Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
CNNA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Focus on a niche market (cannabis for pets).
- Potential first-mover advantage in the EU.
- Proprietary formulations of Cannabis sativa strains.
- Experienced management team.
Bear Case
- Development stage company with limited revenue.
- Small size and limited resources.
- Dependence on regulatory approvals.
- Competition from larger, more established companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
CNNA Latest News
No recent news available for CNNA.
CNNA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CNNA.
Price Targets
Wall Street price target analysis for CNNA.
CNNA MoonshotScore
What does this score mean?
The MoonshotScore rates CNNA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jason R. Tucker
CEO
Jason R. Tucker is the CEO of Cann American Corp. His background includes experience in managing small teams and navigating the complexities of early-stage company development. His expertise lies in the strategic direction of the company, focusing on the development of Cannabis sativa strains for pets in the European Union. He is responsible for overseeing all aspects of the company's operations, from research and development to regulatory compliance.
Track Record: Under Jason R. Tucker's leadership, Cann American Corp. has focused on developing its product pipeline and navigating the regulatory landscape in the European Union. Key milestones include the rebranding of the company and the development of proprietary formulations of Cannabis sativa strains for pets. His focus is on positioning the company for future growth and success in the emerging market of cannabis-based pet products.
CNNA OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cann American Corp. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to the same stringent listing requirements, leading to increased risks for investors. This tier often includes shell companies, companies in bankruptcy, or those unwilling or unable to provide audited financial statements.
- OTC Tier: OTC Other
- Limited or no public disclosure of financial information.
- Low trading volume and liquidity.
- Potential for price manipulation and volatility.
- Higher risk of fraud or mismanagement.
- Lack of regulatory oversight compared to listed exchanges.
- Verify the company's legal status and registration.
- Attempt to obtain audited financial statements.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance.
- Understand the risks associated with investing in OTC Other companies.
- Consult with a financial advisor before investing.
- Company has a registered business address.
- Company has a functioning website.
- CEO is publicly identified.
- Company has a clear business plan (development of Cannabis sativa strains for pets).
- Company rebranded in 2019, indicating some level of activity.
Common Questions About CNNA (Healthcare)
What does the AI Score mean for CNNA?
CNNA holds an AI Score of 42/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Cann American Corp. is a development stage company focused on developing Cannabis sativa strains for pets in the European Union. The company operates in the specialty and generic drug manufacturing …
What does Cann American Corp. do?
Cann American Corp. is a development stage company focused on developing Cannabis sativa strains for pets in the European Union. The company aims to provide alternative treatments for pets using cannabis-based products. Their business model involves research, development, and eventual distribution of these specialized products, targeting a niche market within the broader cannabis industry.
What do analysts say about CNNA stock?
There is currently no available analyst coverage for Cann American Corp. due to its OTC listing and limited disclosure. Key valuation metrics are difficult to assess given the lack of financial information. Growth considerations include the company's ability to secure regulatory approvals, establish a strong market presence in the EU, and differentiate its products from competitors.
What are the main risks for CNNA?
The main risks for Cann American Corp. include regulatory uncertainty in the EU, intense competition from established players in the cannabis industry, and the potential for adverse health effects in pets from cannabis products. The company's limited financial resources and dependence on external funding also pose significant risks.
What are the key factors to evaluate for CNNA?
Cann American Corp. (CNNA) holds an AI score of 42/100 (low). Not financial advice.
How frequently does CNNA data refresh on this page?
CNNA's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CNNA's recent stock price performance?
Cann American Corp. (CNNA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on a niche market (cannabis for pets). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CNNA overvalued or undervalued right now?
Cann American Corp. (CNNA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CNNA before investing?
Before investing in Cann American Corp. (CNNA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited due to the company's OTC listing and lack of public disclosure.
- AI analysis is pending and may provide further insights.